Institute for Behavioral Genetics, 447 UCB, University of Colorado, 1480 30th St., Boulder, CO 80303, USA.
J Pharmacol Exp Ther. 2011 Apr;337(1):187-200. doi: 10.1124/jpet.110.178236. Epub 2011 Jan 12.
Chronic nicotine treatment elicits a brain region-selective increase in the number of high-affinity agonist binding sites, a phenomenon termed up-regulation. Nicotine-induced up-regulation of α4β2-nicotinic acetylcholine receptors (nAChRs) in cell cultures results from increased assembly and/or decreased degradation of nAChRs, leading to increased nAChR protein levels. To evaluate whether the increased binding in mouse brain results from an increase in nAChR subunit proteins, C57BL/6 mice were treated with nicotine by chronic intravenous infusion. Tissue sections were prepared, and binding of [(125)I]3-((2S)-azetidinylmethoxy)-5-iodo-pyridine (A85380) to β2*-nAChR sites, [(125)I]monoclonal antibody (mAb) 299 to α4 nAChR subunits, and [(125)I]mAb 270 to β2 nAChR subunits was determined by quantitative autoradiography. Chronic nicotine treatment dose-dependently increased binding of all three ligands. In regions that express α4β2-nAChR almost exclusively, binding of all three ligands increased coordinately. However, in brain regions containing significant β2*-nAChR without α4 subunits, relatively less increase in mAb 270 binding to β2 subunits was observed. Signal intensity measured with the mAbs was lower than that with [(125)I]A85380, perhaps because the small ligand penetrated deeply into the sections, whereas the much larger mAbs encountered permeability barriers. Immunoprecipitation of [(125)I]epibatidine binding sites with mAb 270 in select regions of nicotine-treated mice was nearly quantitative, although somewhat less so with mAb 299, confirming that the mAbs effectively recognize their targets. The patterns of change measured using immunoprecipitation were comparable with those determined autoradiographically. Thus, increases in α4β2*-nAChR binding sites after chronic nicotine treatment reflect increased nAChR protein.
慢性尼古丁处理会引起大脑区域选择性增加高亲和力激动剂结合位点的数量,这种现象称为上调。细胞培养中的尼古丁诱导α4β2-烟碱型乙酰胆碱受体(nAChRs)的上调是由于 nAChRs 的组装增加和/或降解减少,导致 nAChR 蛋白水平增加。为了评估慢性静脉输注尼古丁后小鼠大脑中增加的结合是否来自 nAChR 亚基蛋白的增加,用尼古丁处理 C57BL/6 小鼠。制备组织切片,并用 [(125)I]3-((2S)-氮杂环丁烷甲氧基)-5-碘吡啶 (A85380)、[(125)I]单克隆抗体(mAb)299 至α4 nAChR 亚基和 [(125)I]mAb 270 至β2 nAChR 亚基定量放射自显影测定β2*-nAChR 结合位点。慢性尼古丁处理剂量依赖性地增加了所有三种配体的结合。在表达几乎完全是α4β2-nAChR 的区域,所有三种配体的结合都协调增加。然而,在含有大量β2*-nAChR 而没有α4 亚基的脑区,观察到 mAb 270 结合β2 亚基的相对较少增加。用 mAb 测量的信号强度低于 [(125)I]A85380,这可能是因为小配体深入到切片中,而大得多的 mAb 遇到了通透性障碍。用 mAb 270 从选定区域的尼古丁处理小鼠的 [(125)I]epibatidine 结合位点免疫沉淀几乎是定量的,尽管用 mAb 299 稍微少一些,这证实了 mAb 可以有效地识别其靶标。用免疫沉淀测量的变化模式与放射自显影测定的模式相当。因此,慢性尼古丁处理后α4β2*-nAChR 结合位点的增加反映了 nAChR 蛋白的增加。